Archivos de Bronconeumología Archivos de Bronconeumología
Arch Bronconeumol 2017;53:695-7 - Vol. 53 Núm.12 DOI: 10.1016/j.arbres.2017.04.011
Scientific letter
In Vitro and In Vivo Evaluation of the Combination of Oscillating Positive Expiratory Pressure and Nebulization: A Randomized Cross-Over Study
Evaluación in vitro e in vivo de la combinación de presión espiratoria positiva oscilante y nebulización: estudio aleatorizado cruzado
Gregory Reychlera,b,c,, , Teresinha Leald, Anne-Sophie Aubriotb,e, Giuseppe Liistroa,c
a Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie, Université Catholique de Louvain, Belgium
b Service de Médecine Physique et Réadaptation, Cliniques universitaires Saint-Luc, Belgium
c Service de Pneumologie, Cliniques universitaires Saint-Luc, Belgium
d Louvain Centre for Toxicology and Applied Pharmacology, Institut de Recherche Expérimentale et Clinique, Secteur des Sciences de la Santé, Université Catholique de Louvain, Belgium
e Centre de Référence pour la Mucoviscidose, Cliniques universitaires Saint-Luc, Belgium
To the Editor:

Positive expiratory pressure (PEP) as airway clearance technique prevents airway closure during expiration, reduces gas trapping in the lung,1 increases collateral ventilation2 and improves spatial ventilation distribution.3 The addition of oscillations promotes mucus mobilization based on the reduced mucus viscosity4 and distributed flows in more airways.5 Oscillating PEP devices have been proposed in cystic fibrosis.6 Simultaneous use of PEP and nebulization is sometimes performed in cystic fibrosis patients even if its clinical benefits are still not well established.

As the drug amount reaching the lungs is essential for the clinical response of drug with a dose-dependent effect, this study aims at evaluating the effect of a new oscillating PEP device combined to a nebulizer on the drug delivery to the lungs.

We connected a jet nebulizer (Sidestream®, Philips-Respironics) (NEB) at the distal end of an oscillating PEP device (Aerobika®, Trudell-Medical) (NEB-OPEP) with a T-piece blocking the extra vent. Each nebulizer was filled with 250mg of amikacin diluted with 3mL of normal saline.

In the in vitro part, a dual-chamber test lung (5600i Dual Adult Test Lung; Michigan Instrument Inc.) driven by a ventilator (Servo-i®, MAQUET) (Fig. 1) simulated an adult breathing pattern (Vt=500mL-RF=12breaths/min-I/E ratio=1:2-breath-hold time=0.25s). An absolute bacterial/viral filter (Air Safety Ltd, Lancashire) was placed between the lung model and NEB-OPEP/NEB to measure the inhaled dose (IND). Another filter placed on the expiratory port collected the exhaled dose (ExD). The mass of amikacin collected on filters during nebulization was quantified using the residual gravimetric method.7 The nebulizer output was calculated by dividing the IND by the nebulization duration. The residual volume was quantified.

Fig. 1.
(0.07MB).

Illustration of the experimental model. 1 – Aerobika, 2 – nebulizer, 3 – filter collecting the inhaled dose, 4 – filter collecting the exhaled dose.

In the in vivo part, after ethical approval (B40320107908) and registration of the trial (NCT02535130), six non-smoker healthy males were recruited. They signed a written informed consent form. They were excluded if they received any antibiotic or aerosolized drug during the month preceding the experiments, for history of cardiovascular and/or pulmonary disease, for allergy to aminoglycosides and for abnormal pulmonary function.

After (1) selection visit, spirometry and medical examination and (2) training to inhale correctly, (3) inhalation and (4) urine sampling were performed. Each subject repeated the steps 3 and 4 in similar conditions using a randomized crossover setting (www.randomizer.org) with a one-week washout period between the two configurations (NEB or NEB-OPEP). The subjects breathed spontaneously through mouthpiece wearing a noseclip.

Just before the experiments, the urinary bladder of the subjects was emptied. Then, urine samples were collected at each spontaneous micturition during the 24h following the nebulization. The volume and timing of micturition were recorded.

After sampling by fluorescence polarization immuno-assay, the total daily amount of amikacin excreted in the urine (Cu max) reflecting lung deposition and the elimination rate constant was calculated using the Michaelis–Menten kinetic model from cumulating amikacin amount measured at each micturition (Cu) and represents the lung dose (LD) (Cu max=Cu×(1eKe·x·t)).

The residual amount of drug was calculated by multiplying residual volume and its final concentration.

In vitro, no difference was found between NEB and NEB-OPEP for IND (34.4% (30.0–38.0) vs 29.6% (26.8–32.0)) and ExD (20.8 (19.6–23.2) vs 25.2% (22.4–28.4)). Nebulizer output was higher for NEB than for NEB-OPEP (1.49±0.14 vs 1.10±0.12mLmin−1; p=0.032).

Six subjects completed the study (21.8±1.0 y – 179.2±8.8cm – 76.5±11.7kg – FEV1: 97±7%). The lung dose was reduced by 40% and the time required to finish the nebulization was 1.2min longer with NEB-OPEP than with NEB (Table 1).

Table 1.

Lung delivery comparison between nebulization used alone and coupled with an oscillating positive expiratory pressure device in 6 healthy subjects.

  NEB  NEB-OPEP  p value 
Lung dose (% ND)  4.7±1.4  2.8±0.2  0.029* 
Time of nebulization (min)  4.3±0.7  5.5±0.6  0.012* 
Residual volume (mL)  0.85±0.08  1.04±0.12  0.044* 

Results are expressed as mean±SD. NEB: nebulizer; NEB-OPEP: nebulizer couple with an oscillating positive expiratory pressure device; ND: nominal dose.

*

p<0.05.

Lung delivery around 5% of the ND with NEB confirmed previous results.8 In addition, our results showed that interposing this new OPEP device between the nebulizer and the patient's mouth reduced the efficiency of the nebulization similarly to results found with other PEP devices under different conditions.9,10 This is clinically important when dose-dependent drugs are administered. The reduced lung delivery could be explained by the impaction of particles in the PEP device that filters the larger particles.9,11 However, this hypothesis was neither verified in our study (similar IND and ExD) nor in a previous study.12

The duration of the nebulization was inversely related to the adherence in CF13 and it is therefore considered as a key factor for an optimal treatment.14,15 In the present study, the small increase in time (+1.2min) related to the NEB-OPEP is compensated by the time saved on the total duration of the treatment administered separately (3.1min). This advantage could be important for the patients needing several daily sessions. However, as suggested by our results, the necessity to nearly double the nebulization duration to reach a similar lung delivery with NEB-OPEP must be taken into account. As Berlinsky showed variable delivery depending on the PEP devices,11 each configuration must be evaluated.

The modified pattern of breathing related to PEP is unfavorable to the nebulization function and explains probably the worst lung delivery related to the combination. The reduction in breathing frequency (7.8 cycles by minutes) when healthy subjects used PEP mask could be considered as advantageous16 but it was associated to a prolonged expiration that contributes to loose particles during the expiratory phase.17 The concomitant reduction in the inspiratory–expiratory ratio contributes certainly to the reduced lung delivery by losing particles during the expiratory phase and it can explain the difference with in vitro results. Some particles are probably exhaled and others are delivered in the atmosphere or the device during this phase.

Some limitations of the study should be discussed. First, the nebulizer was placed at the distal outlet of the PEP device. This configuration is less efficient than that in which the proximal outlet is used for connection,10 although the latter is recommended by the manufacturer. Second, testing healthy subjects omits the clinical and pathophysiological outcomes related to positive expiratory pressure and its oscillations but it permits to evaluate the nebulization function8,18,19 and reduces the variability resulting from mucus plugging or lung disease. Furthermore, even if lung delivery in healthy subjects cannot be extrapolated to patients with respiratory diseases, a similar lung deposition was recently found between healthy subjects and patients with CF.20 Third, each subject was its own control to reduce anatomical, anthropometrical and respiratory influences on lung delivery.

This study suggests that connecting Aerobika at the proximal outlet of a nebulizer is less efficient than using the nebulization alone for drug delivery. However, the gain in time is an argument in favor of the combination.

Acknowledgement

We gratefully acknowledge Julien Anquetil for his help to collect data.

References
1
S. Groth,G. Stafanger,H. Dirksen,J.B. Andersen,M. Falk,M. Kelstrup
Positive expiratory pressure (PEP-mask) physiotherapy improves ventilation and reduces volume of trapped gas in cystic fibrosis
Bull Eur Physiopathol Respir, 21 (1985), pp. 339-343
2
H.A. Menkes,R.J. Traystman
Collateral ventilation
Am Rev Respir Dis, 116 (1977), pp. 287-309 http://dx.doi.org/10.1164/arrd.1977.116.2.287
3
M. Wettstein,L. Radlinger,T. Riedel
Effect of different breathing AIDS on ventilation distribution in adults with cystic fibrosis
4
E.M. Ramos,D. Ramos,D.M. Iyomasa,G.L. Moreira,K.C. Melegati,L.C. Vanderlei
Influence that oscillating positive expiratory pressure using predetermined expiratory pressures has on the viscosity and transportability of sputum in patients with bronchiectasis
J Bras Pneumol, 35 (2009), pp. 1190-1197
5
J.C. Darbee,P.J. Ohtake,B.J. Grant,F.J. Cerny
Physiologic evidence for the efficacy of positive expiratory pressure as an airway clearance technique in patients with cystic fibrosis
Phys Ther, 84 (2004), pp. 524-537
6
C.M. Oermann,M.M. Sockrider,D. Giles,M.K. Sontag,F.J. Accurso,R.G. Castile
Comparison of high-frequency chest wall oscillation and oscillating positive expiratory pressure in the home management of cystic fibrosis: a pilot study
Pediatr Pulmonol, 32 (2001), pp. 372-377
7
N.L. Vecellio,D. Grimbert,J. Bordenave,G. Benoit,Y. Furet,B. Fauroux
Residual gravimetric method to measure nebulizer output
J Aerosol Med, 17 (2004), pp. 63-71 http://dx.doi.org/10.1089/089426804322994479
8
G. Reychler,T. Leal,J. Roeseler,F. Thys,N. Delvau,G. Liistro
Effect of continuous positive airway pressure combined to nebulization on lung deposition measured by urinary excretion of amikacin
Respir Med, 101 (2007), pp. 2051-2055 http://dx.doi.org/10.1016/j.rmed.2007.06.003
9
B.L. Laube,D.E. Geller,T.C. Lin,R.N. Dalby,M. Diener-West,P.L. Zeitlin
Positive expiratory pressure changes aerosol distribution in patients with cystic fibrosis
Respir Care, 50 (2005), pp. 1438-1444
10
F.O. Mesquita,V.C. Galindo-Filho,J.L. Neto,A.M. Galvao,S.C. Brandao,J.B. Fink
Scintigraphic assessment of radio-aerosol pulmonary deposition with the acapella positive expiratory pressure device and various nebulizer configurations
Respir Care, 59 (2014), pp. 328-333 http://dx.doi.org/10.4187/respcare.02291
11
A. Berlinski
In vitro evaluation of positive expiratory pressure devices attached to nebulizers
Respir Care, 59 (2014), pp. 216-222 http://dx.doi.org/10.4187/respcare.02698
12
J. Mitchell,V. Avvakoumova,H. Schneider,R. Ali,M. Nagel
Combining inhalation by a breath-actuated nebulizer (BAN) with exhalation through an oscillating positive pressure device (OPEP) offers the potential for optimal combined therapy
Am J Respir Crit Care Med, 187 (2016), http://dx.doi.org/10.1164/rccm.201301-0085ED
13
H. Heijerman,E. Westerman,S. Conway,D. Touw,G. Doring
Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus
J Cyst Fibros, 8 (2009), pp. 295-315 http://dx.doi.org/10.1016/j.jcf.2009.04.005
14
A. Hogan,M.A. Bonney,J.A. Brien,R. Karamy,P. Aslani
Factors affecting nebulised medicine adherence in adult patients with cystic fibrosis: a qualitative study
Int J Clin Pharm, 37 (2015), pp. 86-93 http://dx.doi.org/10.1007/s11096-014-0043-6
15
G.S. Sawicki,D.E. Sellers,W.M. Robinson
High treatment burden in adults with cystic fibrosis: challenges to disease self-management
J Cyst Fibros, 8 (2009), pp. 91-96 http://dx.doi.org/10.1016/j.jcf.2008.09.007
16
A.M. Hakkinen,H. Uusi-Heikkila,M. Jarvinen,K. Saali,L. Karhumaki
The effect of breathing frequency on deposition of drug aerosol using an inhalation-synchronized dosimeter in healthy adults
Clin Physiol, 19 (1999), pp. 269-274
17
C. O’Callaghan,P.W. Barry
The science of nebulised drug delivery
Thorax, 52 (1997), pp. S31-S44
18
J.G. Hardy,S.P. Newman,M. Knoch
Lung deposition from four nebulizers
Respir Med, 87 (1993), pp. 461-465
19
G. Reychler,A.S. Aubriot,V. Depoortere,F. Jamar,G. Liistro
Effect of drug targeting nebulization on lung deposition: a randomized crossover scintigraphic comparison between central and peripheral delivery
Respir Care, 59 (2014), pp. 1501-1507 http://dx.doi.org/10.4187/respcare.03068
20
P. Brand,M. Schulte,M. Wencker,C.H. Herpich,G. Klein,K. Hanna
Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency
Eur Respir J, 34 (2009), pp. 354-360 http://dx.doi.org/10.1183/09031936.00118408
Corresponding author. (Gregory Reychler gregory.reychler@uclouvain.be)
Copyright © 2017. SEPAR
Arch Bronconeumol 2017;53:695-7 - Vol. 53 Núm.12 DOI: 10.1016/j.arbres.2017.04.011